NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of Directors LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today...

NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 at the ASCO Annual Meeting - First clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL - Early data demonstrates promising efficacy with a predictable and...